Bharat Book Bureau
Bharatbook.com is proud to announce the new report “CombinatoRx Incorporated:
Scope of this report
Contains corporate strategy, value chain presence and SWOT Analysis
Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Research and analysis highlights
CombinatoRx is a biopharmaceutical company engaged in developing synergistic combinations of approved drugs for the treatment of immuno-inflammatory diseases, chronic pain, topical dermatoses, metabolic disease and oncology. It's product line is internally generated from its combination high throughput screening (cHTS) technology.
CombinatoRx's total revenues increased from $0.1 million in 2004 to $13 million in 2006. Prior to 2004, the company did not record revenues.
The table highlights CombinatoRx's absolute revenue growth of +$5 million with sales of $13 million in 2006 increasing to $18 million in 2010, growing at a CAGR of 8%.
Key reasons to read this report
Access all the important information and analysis on the company in a single report
Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain
Gain access to company's adjusted five year financial data along with key ratios and market capitalization
For more information kindly visit: http://www.bharatbook.com/
